Visualitzant O - Articles científics per títol

Finding MYCure

Beaulieu, Marie-Eve; Soucek, Laura (Taylor and Francis, 2019-06-20)

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

Pernas, Sonia; Villagrasa, Patricia; Vivancos Prellezo, Ana; Scaltriti, Maurizio; Rodon Ahnert, Jordi; Burgués, Octavio; Nuciforo, Paolo Giovanni; Antunes de Melo Oliveira, Ana Mafalda (Frontiers Media, 2021-11-04)

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

Ameratunga, Malaka; Braña Garcia, Irene; Bono, Petri; Postel-Vinay, Sophie; Plummer, Ruth; Aspegren, John (Springer Nature, 2020-12-08)

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Yap, Timothy A.; Vieito Villar, Maria; Baldini, Capucine; Sepúlveda, Juan Manuel; Kondo, Shunsuke; Simonelli, Matteo (American Association for Cancer Research, 2021-12)

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

Salamero García, Olga; Willekens, Christophe; Pérez-Simón, José Antonio; Pigneux, Arnaud; Récher, Christian; Carpio Segura, Cecilia Carmen; Bosch Albareda, Francesc; Montesinos, Pau (American Society of Clinical Oncology, 2020-12-20)

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Piha-Paul, Sarina; Geva, Ravit; Tan, Tira; Lim, Darren Wan-Teck; Hierro Carbó, Cinta; Doi, Toshikiko (BMJ, 2021-08)

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

Davis, Elizabeth J; Martín Liberal, Juan Jesús; Kristeleit, Rebecca S; Cho, Daniel; Blagden, Sarah P; Berthold, Dominik; Vieito Villar, Maria (BMJ, 2022-10)

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

Boyiadzis, Michael; Desai, Pinkal; Daskalakis, Nikki; Donnellan, William; Ferrante, Lucille; Goldberg, Jenna D.; Salamero García, Olga (Wiley, 2023-03)

First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

Narayan, Rupa; Alfonso-Piérola, Ana; Donnellan, William; Abdul-Hay, Maher; Molero , Antonieta; Platzbecker, Uwe (Wiley, 2024-03-18)

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

Martín Liberal, Juan Jesús; Hollebecque, Antoine; Jungels, Christiane; Martin-Romano, Patricia; Rodon Ahnert, Jordi; Aftimos, Philippe (Springer Nature, 2020-10)

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

Felip Font, Enriqueta; Morgensztern, Daniel; Trigo, José Manuel; Moreno, Victor; Curigliano, Giuseppe; Rutkowski, Piotr (Springer, 2022-04)

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study

Prager, Gerald W; Westphalen, C Benedikt; D'Esquermes, Nathalie; Ferreras, Anabel; Macarulla Mercadé, Teresa; Taieb, Julien; Melisi, Davide (BMJ, 2020-01-20)

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Ready, Neal; Audigier-Valette, Clarisse; Goldman, Jonathan W.; Felip Font, Enriqueta; Ciuleanu, Tudor; Garcia Campelo, Rosario (BMJ, 2023-02)

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Paz-Ares, Luis; Bennouna, Jaafar; Schenker, Michael; Cheng, Ying; FELIP, ENRIQUETA; Cobo, Manuel; Ciuleanu, Tudor Eliade (Elsevier, 2023-02)

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Reck, M.; Ciuleanu, Tudor; Schenker, M.; Zurawski, B.; Menezes, J.; Felip Font, Enriqueta; Cobo, Manuel (Elsevier, 2021-10)

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

Gonzalez-Martin, Antonio; Harter, Philipp; Lorusso, Domenica; Moore, Kathleen N; Oaknin Benzaquen, Ana Mazaltob; Banerjee, Susana (BMJ, 2020-12-11)

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Fizazi, Karim; Fay, Andre P; De Giorgi, Ugo; Azad, Arun; Carles, Joan; Matsubara, Nobuaki (Nature Portfolio, 2024-01)

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

Van Cutsem, Eric; Danielewicz, I.; Saunders, M. P.; Pfeiffer, P.; Argilés Martinez, Guillem; Borg, Christophe (Springer Nature, 2022-06-01)

Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

Feliciano Aguirre, Andrea F; Gonzalez Amaya, Lucila; Garcia Mayea, Yoelsis; Mir Perez, Cristina; Artola, Mireia; Barragán, Nieves; Castellví Vives, Josep; Benavente Norza, Sergio; Ramon y Cajal Agüeras, Santiago; Espinosa Bravo, Martin; Cortés Castan, Javier; Lleonart Pajarin, Matilde (Frontiers Media, 2020-11-03)

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Borghaei, Hossein; Gettinger, Scott; Vokes, Everett; Chow, Laura; Burgio, Marco Angelo; de Castro Carpeno, Javier; Felip Font, Enriqueta (American Society of Clinical Oncology, 2021-03-01)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

Finding MYCure

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

Finding MYCure ﻿

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study ﻿

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours ﻿

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer ﻿

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia ﻿

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas ﻿

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors ﻿

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia ﻿

First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome ﻿

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours ﻿

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers ﻿

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study ﻿

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817 ﻿

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations ﻿

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update ﻿

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion ﻿

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial ﻿

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study ﻿

Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals ﻿

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Finding MYCure

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer